Last reviewed · How we verify
Linagliptin Single Tablet
At a glance
| Generic name | Linagliptin Single Tablet |
|---|---|
| Sponsor | Boehringer Ingelheim |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Viral upper respiratory tract infection
- Blood ketone body increased
- Headache
- Back pain
- Constipation
- Contusion
- Nasopharyngitis
- Periodontitis
- Urinary tract infection
- Lipase increased
- Weight decreased
- Hyperglycaemia
Key clinical trials
- Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets (PHASE1)
- A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults: Fed State Study (PHASE1)
- To Compare and Evaluate the Oral Bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg Filmcoated Tablets With That of Glyxambi 10 mg/ 5 mg Film-coated Tablets in Healthy, Adult, Human Subjects Under Fasting Conditions. (PHASE1)
- A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults (PHASE1)
- Bioequivalence Study to Compare Empagliflozin + Linagliptin 25 mg/5 mg Film-coated Tablets Versus Glyxambi 25 mg/ 5 mg Film-coated Tablets (PHASE1)
- Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes (PHASE3)
- The Bioequivalence Study of Linagliptin 5 mg Film-coated Tablet in Healthy Thai Volunteers (PHASE1)
- Bioequivalence Study of Empagliflozin And Linagliptin Tablets in Healthy Chinese Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Linagliptin Single Tablet CI brief — competitive landscape report
- Linagliptin Single Tablet updates RSS · CI watch RSS
- Boehringer Ingelheim portfolio CI